Tim joined RoukenBio as Director of Molecular Biology in 2020. After completing an undergraduate Masters in Biochemistry and obtaining a PhD in Molecular Biology from the University of Cambridge, he began his industry career as a research scientist within the Protein Sciences Team at MedImmune. As part of various projects, he was responsible for cell line development and protein purification activities to enable lead generation and isolation activities throughout the research phase of the antibody therapeutic development pipeline.
In 2016, Tim joined TC BioPharm as a Product Development Manager and played a key role in establishing the early-stage CAR-T program. Since joining RoukenBio, Tim has overseen the creation of novel rapid cell line generation platform systems for inducible expression of target antigens, generating new intellectual property for the company. At the same time, he has helped to expand the company’s service portfolio to include custom cell line generation as a core service. He is co-inventor in several patents in the field of CAR-T cell therapies and cell line development.
“Throughout my career I have been driven by the desire to play a part in the development of new therapeutics which make a difference in patients’ lives. At RoukenBio, I particularly enjoy the variety of the projects I am involved in and the different therapeutic approaches that our clients employ, each one with unique challenges and opportunities.” – Tim London.
Resources
Research Posters
10 November 2026
|5 min read
This research poster presents an integrated, human-relevant assay cascade for antibody-drug conjugate (ADC) evaluation, connecting target engagement and intracellular payload delivery with target-density dependence, tumour-cell killing, Fc-mediated immune activity and response within the tumour microenvironment. By combining controlled cellular models, primary human immune assays and patient-derived tumour models, the approach generates mechanism-linked insights to support more informed ADC candidate ranking and lead selection
Research Posters
16 July 2025
|5 min read
Understanding how antibody-based drugs interact with targets at different expression levels is key to optimising their safety and efficacy. Traditional methods struggle to measure binding kinetics in real cellular environments. This study uses the IndEx-2 system and single-cell Interaction Cytometry to reveal how target density affects drug binding in a more physiologically relevant context.
Webinars
12 June 2025
|4 min read
Watch our latest Labroots webinar on LocIn, our targeted integration system.
